Literature DB >> 20022439

Mild phenotype in Pelizaeus-Merzbacher disease caused by a PLP1-specific mutation.

Hitoshi Osaka1, Shiro Koizume, Haruhiko Aoyama, Hiroko Iwamoto, Seiji Kimura, Jun-Ichi Nagai, Kenji Kurosawa, Sumimasa Yamashita.   

Abstract

We present the case of a 26 year-old man who developed normally until he began having difficulty walking at age 12. He subsequently became unable to stand at 15 years old and exhibited mental regression and generalized tonic convulsions by age 20. Magnetic resonance imaging revealed incomplete myelination of cerebral white matter, which resembled that of Pelizaeus-Merzbacher disease. By sequencing the proteolipid protein 1 (PLP1) gene, we found a novel mutation (c.352_353delAG (p.Gly130fs)) in the latter half of exon 3 (exon 3B) that is spliced out in the DM20 isoform. Exon 3B mutations are known to cause a mild phenotype since they do not disturb DM20 production. Mutations that truncate PLP1 correlate with a mild phenotype by activating the nonsense-mediated decay mechanism that specifically detects and degrades mRNAs containing a premature termination codon. This attenuates the production of toxic mutant PLP1. The very mild presentation in the present case seems to be derived from the unique nature of the mutation, which preserves DM20 production and decreases mutant PLP1.
Copyright © 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20022439     DOI: 10.1016/j.braindev.2009.11.004

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  6 in total

1.  Yeast Two-Hybrid Screening for Proteins that Interact with the Extracellular Domain of Amyloid Precursor Protein.

Authors:  You Yu; Yinan Li; Yan Zhang
Journal:  Neurosci Bull       Date:  2016-03-09       Impact factor: 5.203

2.  Altered PLP1 splicing causes hypomyelination of early myelinating structures.

Authors:  Sietske H Kevelam; Jennifer R Taube; Rosalina M L van Spaendonk; Enrico Bertini; Karen Sperle; Mark Tarnopolsky; Davide Tonduti; Enza Maria Valente; Lorena Travaglini; Erik A Sistermans; Geneviève Bernard; Coriene E Catsman-Berrevoets; Clara D M van Karnebeek; John R Østergaard; Richard L Friederich; Mahmoud Fawzi Elsaid; Jolanda H Schieving; Maja Tarailo-Graovac; Simona Orcesi; Marjan E Steenweg; Carola G M van Berkel; Quinten Waisfisz; Truus E M Abbink; Marjo S van der Knaap; Grace M Hobson; Nicole I Wolf
Journal:  Ann Clin Transl Neurol       Date:  2015-05-01       Impact factor: 4.511

3.  Morpholino Antisense Oligomers as a Potential Therapeutic Option for the Correction of Alternative Splicing in PMD, SPG2, and HEMS.

Authors:  Stephanie Tantzer; Karen Sperle; Kaitlin Kenaley; Jennifer Taube; Grace M Hobson
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-05       Impact factor: 8.886

4.  Expanding the Clinical and Mutational Spectrum of the PLP1-Related Hypomyelination of Early Myelinated Structures (HEMS).

Authors:  Francesco Nicita; Chiara Aiello; Gessica Vasco; Massimiliano Valeriani; Fabrizia Stregapede; Andrea Sancesario; Michela Armando; Enrico Bertini
Journal:  Brain Sci       Date:  2021-01-13

5.  Exome sequencing reveals a novel PLP1 mutation in a Moroccan family with connatal Pelizaeus-Merzbacher disease: a case report.

Authors:  Jaber Lyahyai; Bouchra Ouled Amar Bencheikh; Siham C Elalaoui; Maria Mansouri; Lamia Boualla; Alexandre DIonne-Laporte; Dan Spiegelman; Patrick A Dion; Patrick Cossette; Guy A Rouleau; Abdelaziz Sefiani
Journal:  BMC Pediatr       Date:  2018-02-27       Impact factor: 2.125

6.  Novel PLP1 Mutations Identified With Next-Generation Sequencing Expand the Spectrum of PLP1-Associated Leukodystrophy Clinical Phenotypes.

Authors:  Rebecca L Margraf; Jacob Durtschi; Bryan Krock; Tara M Newcomb; Joshua L Bonkowsky; Karl V Voelkerding; Pinar Bayrak-Toydemir; Richard E Lutz; Kathryn J Swoboda
Journal:  Child Neurol Open       Date:  2018-07-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.